LONDON, November 30 /PRNewswire/ -- Inpharmatica Ltd, the selective drug discovery company, announced today that it has signed a non-exclusive Biopendium Online (TM) subscription with Shionogi & Co. Ltd. Shionogi manufactures and markets pharmaceutical products, diagnostics and other related products.
Biopendium (TM) is the advanced protein annotation component of PharmaCarta (TM), Inpharmatica's gene to candidate platform. Shionogi is the fifth Japanese Biopendium (TM) subscriber and the third this year to use the online version. Other subscribers include Pfizer, Serono, Aventis and UCB Pharma. In addition to Inpharmatica's in-house and collaborative drug development activities, licensing agreements with pharmaceutical and biotechnology companies reinforce the company's revenue earning capabilities.
Biopendium (TM) provides comprehensive sequence annotation for over 150 organisms, making it the world's largest pre-computed, annotation database. Superior annotation is generated by moving beyond traditional text-based data to a system that incorporates pharmaceutically relevant, protein 3D structure and ligand information. Through Biopendium (TM), Shionogi will have immediate access to high quality annotation for their protein sequences, including the human genome, 'model' organisms (rat, mouse, dog), and bacteria and viral genomes all of which will assist Shionogi in their mission to create superior healthcare pharmaceuticals.
The recent addition of popular, microarray analysis modules to Biopendium (TM), together with Inpharmatica's unique Drugged Domain sequence resource, also enables rapid annotation and prioritisation of experimental data. Shionogi and all other subscribers will benefit from future developments with each new quarterly release.
The Agreement was secured in conjunction with PharmaDesign, Inpharmatica's sales and marketing partner in Japan. MDL Information Systems markets Biopendium (TM) in the rest of the world.
Commenting on the announcement, Dr Vimal Mehta, SVP, Business Development, said:
"To add a third Japanese subscriber to Biopendium Online (TM) this year is a fantastic achievement for the Company. We are looking forward to developing our relationship with Shionogi and are confident that they will find it as invaluable to their drug discovery efforts as all of our other subscribers".
About Inpharmatica: (http://www.inpharmatica.com/)
Founded in 1998, Inpharmatica Ltd is a selective drug discovery company using predictive technologies to improve speed and productivity. Focusing on highly druggable targets, its unique proprietary platform, PharmaCarta (TM), is an integrated suite of informatics-based technologies fully capable of rapid gene to candidate operations. Inpharmatica's lead discovery programme is focused on generating pre-clinical candidates against 16 novel nuclear receptors - proteins widely considered to be both druggable and of high therapeutic interest. Other significant programmes include novel secreted proteins/antibody targets, ion channels, P450 enzymes, metalloproteinases and progestin receptors.
The Company employs approximately 100 professionals at its UK locations in London and Cambridge, with business development headed in North America. Inpharmatica has raised some GBP35m from leading venture capitalists and has sales/collaboration partnerships with Serono, Pfizer, GSK, Aventis, P&G, Daiichi, Riken, Taisho, Chugai, MDL, Ionix, CellZome and Galapagos.
About Shionogi: (http://www.shionogi.co.jp/)
Shionogi & Co., Ltd. is a major research-driven Japanese pharmaceutical manufacturer. The company's primary businesses are research and development, manufacturing, marketing, and import and export sales of pharmaceuticals and diagnostics. Development of original, world-class pharmaceuticals is essential for Shionogi to carry out its corporate mission of continually providing the superior medicines essential to people's health. In order to create novel products, Shionogi is concentrating investment of its resources on focused research fields and diseases such as infectious diseases, cancer and inflammatory diseases, metabolic diseases, and central nervous system disorders.
For more details, please visit http://www.shionogi.co.jp/